Skip Navigation


European Heart Journal Advance Access originally published online on July 13, 2005
European Heart Journal 2005 26(18):1930; doi:10.1093/eurheartj/ehi416
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
26/18/1930    most recent
ehi416v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Ghosh, P. K.
Right arrow Articles by Khamar, B. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ghosh, P. K.
Right arrow Articles by Khamar, B. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Comment on activity of commercial streptokinase preparations: issue of sub-standard life-saving drugs

Prasanta K. Ghosh

Cadila Pharmaceuticals Ltd
Sarkhej-Dholka Highway
Bhat
Ahmedabad 382210
India
E-mail address: pghosh@cadilapharma.co.in

Bakulesh M. Khamar

Cadila Pharmaceuticals Ltd
Sarkhej-Dholka Highway
Bhat
Ahmedabad 382210
India

The first 10% of the full text of this article appears below.

We read the pre-clinical research paper of Hermentin et al.1 with interest. The paper compares the potency and purity of different commercial streptokinase (SK) preparations.

The paper, inter alia, analyses STPase Batches 2008 and 2009 manufactured by Cadila . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?